凤凰网首页 手机凤凰网

凤凰卫视
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
免费注册
海普瑞(002399)公告正文

海普瑞:2018年第三季度报告全文

公告日期 2018-10-30
股票简称:海普瑞 股票代码:002399
               深圳市海普瑞药业集团股份有限公司 2018 年第三季度报告全文




深圳市海普瑞药业集团股份有限公司

    2018 年第三季度报告全文




          2018 年 10 月




                                                                     1
                                 深圳市海普瑞药业集团股份有限公司 2018 年第三季度报告全文




                         第一节 重要提示


    公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真

实、准确、完整,不存在虚假记载、误导性陈述或者重大遗漏,并承担个别和

连带的法律责任。

    所有董事均已出席了审议本次季报的董事会会议。

    公司负责人李锂、主管会计工作负责人张斌及会计机构负责人(会计主管人

员)张斌声明:保证季度报告中财务报表的真实、准确、完整。




                                                                                       2
                                                          深圳市海普瑞药业集团股份有限公司 2018 年第三季度报告全文




                                        第二节 公司基本情况

一、主要会计数据和财务指标

公司是否需追溯调整或重述以前年度会计数据
√ 是 □ 否
追溯调整或重述原因
同一控制下企业合并

                                                                                                          本报告期末比上年度
                                                                        上年度末
                              本报告期末                                                                        末增减

                                                         调整前                       调整后                    调整后

总资产(元)                   13,541,260,399.31       13,189,413,531.98            14,211,473,944.00                    -4.72%

归属于上市公司股东的
                                5,836,073,649.51        7,580,397,982.60             7,927,339,495.26                  -26.38%
净资产(元)

                                                                                                                      年初至报
                                                                   本报告期
                                                                                                                      告期末比
                                            上年同期               比上年同 年初至报告           上年同期
                         本报告期                                                                                     上年同期
                                                                     期增减     期末
                                                                                                                         增减

                                       调整前        调整后         调整后                  调整前         调整后      调整后

                         1,123,690,7 738,229,008 721,469,457                  3,332,009,3 1,788,269,6 1,868,188,1
营业收入(元)                                                       55.75%                                              78.36%
                              14.25           .91         .15                       86.88       21.98         95.43

归属于上市公司股东的     206,706,175 45,112,627. 78,602,888.                  450,883,299 52,562,719. 82,889,507.
                                                                    162.98%                                            443.96%
净利润(元)                     .00            57            85                      .07            94          66

归属于上市公司股东的
                         196,017,347 49,070,398. 81,954,565.                  429,585,489 45,253,666. 72,280,107.
扣除非经常性损益的净                                                139.18%                                            494.33%
                                 .45            73            66                      .98            50          23
利润(元)

经营活动产生的现金流     365,389,675 -214,538,96 -232,300,02                  494,255,748 -387,469,29 -464,206,5
                                                                    257.29%                                            206.47%
量净额(元)                     .36         2.56        9.49                         .01        9.92         93.50

基本每股收益(元/股)        0.1657        0.0362      0.0630       163.02%        0.3615      0.0421        0.0665    443.61%

稀释每股收益(元/股)        0.1657        0.0362      0.0630       163.02%        0.3615      0.0421        0.0665    443.61%

加权平均净资产收益率          3.09%        0.60%        1.00%         2.09%        6.18%       0.67%         1.02%        5.16%

非经常性损益项目和金额
√ 适用 □ 不适用




                                                                                                                                  3
                                                       深圳市海普瑞药业集团股份有限公司 2018 年第三季度报告全文


                                                                                                               单位:元

                           项目                              年初至报告期期末金额                     说明

非流动资产处置损益(包括已计提资产减值准备的冲销部分)                        20,627.74

计入当期损益的政府补助(与企业业务密切相关,按照国家统
                                                                          21,330,727.05
一标准定额或定量享受的政府补助除外)

除上述各项之外的其他营业外收入和支出                                       7,063,157.60

减:所得税影响额                                                           1,426,500.89

       少数股东权益影响额(税后)                                          5,690,202.41

合计                                                                      21,297,809.09                --

对公司根据《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》定义界定的非经常性损益项目,以及把《公
开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》中列举的非经常性损益项目界定为经常性损益的项目,应
说明原因
□ 适用 √ 不适用
公司报告期不存在将根据《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》定义、列举的非经常性损益
项目界定为经常性损益的项目的情形。


二、报告期末股东总数及前十名股东持股情况表

1、普通股股东和表决权恢复的优先股股东数量及前 10 名股东持股情况表

                                                                                                               单位:股

                                                           报告期末表决权恢复的优先
报告期末普通股股东总数                            28,388                                                              0
                                                           股股东总数(如有)

                                               前 10 名股东持股情况

                                                                              持有有限售条件       质押或冻结情况
            股东名称                股东性质    持股比例       持股数量
                                                                                的股份数量       股份状态      数量

深圳市乐仁科技有限公司       境内非国有法人         38.01%      474,029,899                  0

乌鲁木齐金田土股权投资合伙
                             境内非国有法人         32.72%      408,041,280                  0
企业(有限合伙)

乌鲁木齐水滴石穿股权投资合
                             境内非国有法人          3.72%       46,425,600                  0
伙企业(有限合伙)

乌鲁木齐飞来石股权投资有限
                             境内非国有法人          3.23%       40,320,000                  0 质押          32,980,000
公司

深圳市海普瑞药业股份有限公
                             其他                    1.65%       20,618,035                  0
司-第二期员工持股计划

黄光伟                       境内自然人              0.69%        8,654,100                  0

黄镇                         境内自然人              0.68%        8,500,000                  0

应一城                       境内自然人              0.38%        4,689,086                  0



                                                                                                                          4
                                                       深圳市海普瑞药业集团股份有限公司 2018 年第三季度报告全文


中国建设银行股份有限公司-
长城品牌优选混合型证券投资 其他                      0.30%       3,700,925               0
基金

长安国际信托股份有限公司-
长安信托-长安投资 591 号证 其他                     0.26%       3,296,200               0
券投资集合资金信托计划

                                         前 10 名无限售条件股东持股情况

                                                                                     股份种类
               股东名称               持有无限售条件股份数量
                                                                          股份种类                数量

深圳市乐仁科技有限公司                               474,029,899 人民币普通股                       474,029,899

乌鲁木齐金田土股权投资合伙企业
                                                     408,041,280 人民币普通股                       408,041,280
(有限合伙)

乌鲁木齐水滴石穿股权投资合伙企业
                                                      46,425,600 人民币普通股                        46,425,600
(有限合伙)

乌鲁木齐飞来石股权投资有限公司                        40,320,000 人民币普通股                        40,320,000

深圳市海普瑞药业股份有限公司-第
                                                      20,618,035 人民币普通股                        20,618,035
二期员工持股计划

黄光伟                                                 8,654,100 人民币普通股                            8,654,100

黄镇                                                   8,500,000 人民币普通股                            8,500,000

应一城                                                 4,689,086 人民币普通股                            4,689,086

中国建设银行股份有限公司-长城品
                                                       3,700,925 人民币普通股                            3,700,925
牌优选混合型证券投资基金

长安国际信托股份有限公司-长安信
托-长安投资 591 号证券投资集合资                      3,296,200 人民币普通股                            3,296,200
金信托计划

                                    深圳市乐仁科技有限公司和乌鲁木齐金田土股权投资合伙企业(有限合伙)的股东
                                    (合伙人)为李锂和李坦,乌鲁木齐飞来石股权投资有限公司的股东为李锂,乌鲁
                                    木齐水滴石穿股权投资合伙企业(有限合伙)的合伙人为单宇和李坦,李锂和李坦
上述股东关联关系或一致行动的说明 为夫妻关系,单宇和李坦为兄妹关系,单宇参与公司第二期员工持股计划,参加份
                                    额为 38.88%。黄光伟和黄镇为叔侄关系。除上述情况外,公司未知其他前十名股东
                                    之间是否存在关联关系,也未知是否属于一致行动人;公司未知其他前十名无限售
                                    条件股东之间是否存在关联关系,也未知是否属于一致行动人。

                                    前 10 名普通股股东中,黄光伟通过中国中投证券有限责任公司客户信用交易担保
                                    证券账户持有公司股票 8,654,100 股,占公司总股本的 0.69%。黄镇通过中国中投证
前 10 名普通股股东参与融资融券业
                                    券有限责任公司客户信用交易担保证券账户持有公司股票 8,500,000 股,占公司总
务情况说明(如有)
                                    股本的 0.68%;应一城通过国信证券股份有限公司客户信用交易担保证券账户持有
                                    公司股票 1,441,464 股,占公司总股本的 0.12%。

公司前 10 名普通股股东、前 10 名无限售条件普通股股东在报告期内是否进行约定购回交易
□ 是 √ 否


                                                                                                                     5
                                                     深圳市海普瑞药业集团股份有限公司 2018 年第三季度报告全文


公司前 10 名普通股股东、前 10 名无限售条件普通股股东在报告期内未进行约定购回交易。


2、公司优先股股东总数及前 10 名优先股股东持股情况表

□ 适用 √ 不适用




                                                                                                           6
                                                          深圳市海普瑞药业集团股份有限公司 2018 年第三季度报告全文




                                             第三节 重要事项

一、报告期主要财务数据、财务指标发生变动的情况及原因

√ 适用 □ 不适用
1.资产负债表项目变动原因

       项目          本报告期末        本报告期初         同比增减                            变动原因

 货币资金           2,372,117,010.84   3,597,128,234.63        -34.06% 报 告 期 内 母 公 司 支 付 部 分 多 普 乐 股 权 收 购 款
                                                                        12.24亿元所致

 其他应收款          235,653,956.87     375,111,510.85         -37.18% 报告期内母公司收到到期定期存款的利息1.34亿
                                                                        元所致

 长期应收款            6,413,640.17       2,529,274.60         153.58% 报告期内孙公司SPL应收利息增加所致

 长期股权投资        365,717,491.67     621,440,389.73         -41.15% 报告期内母公司对RVX的长期股权投资按照权益
                                                                        法核算确认投资损失所致

 应付票据及应付      287,468,211.60     187,288,194.45          53.49% 报告期内孙公司深圳天道因业务规模增长导致采
账款                                                                    购增加,进而导致应付账款增加所致

 预收款项            162,163,186.70      70,181,022.14         131.06% 报告期内孙公司赛湾生物预收款增加所致

 应交税费            108,900,914.54      31,040,540.12         250.83% 报告期内母公司及孙公司深圳天道因利润总额增
                                                                        加计提所得税增加所致

 其他应付款         1,398,006,155.20    252,719,705.59         453.18% 报告期内母公司增加未支付多普乐股权收购款
                                                                        12.00亿元所致

 一年内到期的非 1,027,025,577.04       1,577,762,267.59        -34.91% 报告期内子公司美国海普瑞及孙公司深圳天道到
流动负债                                                                期偿还长期借款所致

 其他流动负债          1,907,119.10       2,933,348.74         -34.98% 报告期内孙公司SPL和赛湾生物支付预提的费用
                                                                        所致

 长期借款           1,472,642,746.08    831,819,445.60          77.04% 报告期内母公司及孙公司SPL长期借款增加所致

 递延收益             29,574,859.60      42,344,909.20         -30.16% 报告期内母公司退回政府补助及子公司深圳君圣
                                                                        泰的递延收益结转至营业外收入所致

 资本公积           2,147,908,689.56   4,550,075,084.56        -52.79% 报告期内母公司溢价收购多普乐冲减资本公积所
                                                                        致

其他综合收益         145,528,444.81     229,456,893.23         -36.58% 报告期内母公司的可供出售金融资产公允价值变
                                                                        动损失增加以及因人民币贬值导致外币报表折算
                                                                        差额增加共同影响所致




                                                                                                                             7
                                                         深圳市海普瑞药业集团股份有限公司 2018 年第三季度报告全文


2.利润表项目变动原因

     项目          本报告期            上年同期          同比增减                       变动原因

营业收入         3,332,009,386.88     1,868,188,195.43         78.36% 报告期内母公司的肝素钠原料药的销量和销售单
                                                                     价上涨、孙公司SPL的胰酶原料药的销量和销售
                                                                     单价上涨以及孙公司深圳天道及其子公司依诺制
                                                                     剂的销量和销售单价上涨共同影响所致

营业成本         2,019,706,086.22     1,313,069,041.93         53.82% 报告期内母公司的肝素钠原料药的销量和销售单
                                                                     位成本上涨、孙公司SPL的胰酶原料药的销量增
                                                                     加以及孙公司深圳天道及其子公司依诺制剂的销
                                                                     量和销售单位成本上涨共同影响所致

销售费用          189,076,617.66        73,192,717.56         158.33% 报告期内孙公司深圳天道及其子公司市场推广费
                                                                     增加所致

研发费用          116,546,165.76        67,521,505.52          72.61% 报告期内子公司君圣泰以及孙公司深圳天道的研
                                                                     发费用增加所致

财务费用           15,037,943.91        66,030,264.56         -77.23% 报告期内母公司短期借款利息增加、利息收入减
                                                                     少以及人民币贬值导致内部往来款产生汇兑收益
                                                                     增加共同影响所致

其他收益           21,330,727.05        14,161,619.72          50.62% 报告期内母公司及子公司君圣泰的政府补助增加
                                                                     所致

投资收益          -187,693,804.55        1,436,834.40      -13163.01% 报告期内母公司及子公司美国海普瑞权益法核算
                                                                     的长期股权投资损失和子公司枫海资本的投资收
                                                                     益增加共同影响所致

公允价值变动收                 0.00      -6,987,616.08        100.00% 去年同期货币交叉掉期平仓结算结转公允价值所
益                                                                   致

资产处置收益            118,064.09         867,055.21         -86.38% 报告期内固定资产处置收益减少所致

营业利润          530,617,038.80        86,028,737.60         516.79% 报告期内销售毛利增加、财务费用减少带来的利
                                                                     润增加部分被增加的销售费用和投资损失抵销共
                                                                     同所致

营业外收入             7,133,506.61      1,123,145.70         535.14% 报告期内公司收到违约收入及其他杂项收入增加
                                                                     所致

营业外支出              167,785.36       2,049,480.91         -91.81% 报告期内母公司未发生延期滞纳金所致

利润总额          537,582,760.05        85,102,402.39         531.69% 报告期内营业利润增加所致

所得税费用        108,635,809.02        10,465,069.56         938.08% 报告期内利润总额增加所致

净利润            428,946,951.03        74,637,332.83         474.71% 报告期内利润总额增加及所得税增加共同影响所
                                                                     致

少数股东损益       -21,936,348.04        -8,252,174.83        165.83% 报告期内控股子公司亏损增加所致

其他综合收益的     -84,130,321.69     -165,860,440.59          49.28% 报告期内人民币贬值导致外币报表折算差额增加
税后净额                                                             所致


                                                                                                               8
                                                           深圳市海普瑞药业集团股份有限公司 2018 年第三季度报告全文




3.现金流量表项目变动原因

       项目            本报告期          上年同期          同比增减                       主要变动原因

经营活动产生的        494,255,748.01     -464,206,593.50        206.47% 报告期内销售同比增加,销售商品、提供劳务收
  现金流量净额                                                          到的现金同比增加导致经营活动现金流入增加所
                                                                        致

投 资 活 动 产 生 的 -1,579,670,052.63   -521,034,254.59        203.18% 报告期内取得子公司支付的现金同比增加以及处
现金流量净额                                                            置子公司收到的现金同比增加,购建固定资产支
                                                                        付的现金同比减少综合影响导致投资活动现金流
                                                                        出增加所致

筹资活动产生的       -176,024,145.61     517,085,085.69        -134.04% 报告期内偿还银行借款支付的现金大于向银行借
现金流量净额                                                            款收到的现金所致

汇率变动对现金          42,272,277.90     -13,379,674.44        415.94% 报告期内人民币贬值而去年同期人民币升值导致
的影响                                                                  汇兑收益增加

现 金 及 现 金 等 价 -1,219,166,172.33   -481,535,436.84       -153.18% 报告期内经营活动产生现金流入净额增加,汇率
物净增加额                                                              变动对现金的影响金额增加,以及投资活动和筹
                                                                        资活动产生的现金流出净额增加,共同所致




二、重要事项进展情况及其影响和解决方案的分析说明

√ 适用 □ 不适用


     1、 2014 年 11 月 3 日 , 公 司 第 三 届 董 事 会 第 五 次 会 议 审 议 通 过 《 关 于 公 司 使 用 自 有 资 金 对 TPG

BIOTECHNOLOGY PARTNERS IV, L.P.进行投资的议案》,同意公司使用17,358,389美元自有资金对TPG

Biotechnology Partners IV, L.P.进行投资(对应份额16,150,000美元),同时以500万美元自有资金购

买有限合伙人TPG Holdings I, L.P.和TPG Holdings II, L.P.认缴TPG的500万美元份额,共计投资

22,358,389美元。报告期内,公司按照投资付款通知,实际支付639,999美元,同时收到TPG分红815,037

美元。截至本公告日,已累计支付21,623,680美元。

     2、 2015年3月18日,公司第三届董事会第八次会议审议通过了《关于设立产业并购基金的议案》,

决定设立深圳市德康投资发展有限公司,注册资本1,000万元。德康投资与北京鑫羊投资管理有限责任公

司、北京格兰德丰投资管理中心(有限合伙)等共同成立北京枫海资本管理中心(有限合伙),枫海资本

认缴出资总额250万元。待枫海资本成立后,再由该枫海资本作为普通合伙人,海普瑞作为有限合伙人共

同成立“深圳枫海资本并购基金(有限合伙)”。报告期内,公司按照投资付款通知,实际支付990万元

人民币。截至本公告日,已累计支付21,342.35万元人民币。



                                                                                                                       9
                                                   深圳市海普瑞药业集团股份有限公司 2018 年第三季度报告全文


    3、 2015年8月27日,公司第三届董事会第十五次会议审议通过了《关于设立新药基金的议案》,详

细内容参见2015年8月29日刊登于《证券时报》、《中国证券报》、《上海证券报》、《证券日报》和巨

潮资讯网 www.cninfo.com.cn 的《关于设立新药基金的公告》。报告期内,公司未收到投资付款通知。

截至本公告日,已累计支付8,925万人民币。

    4、 2016年1月22日,公司召开第三届董事会第十九次会议审议通过了《关于对全资子公司增资并参

与投资设立医疗基金的议案》,决定以自有资金2,000万美元对全资子公司香港海普瑞增资,用于参与投

资设立ORI Healthcare Fund, L.P.。2016年9月20日,公司第三届董事会第二十六次会议审议通过《关于

全资子公司对ORI Healthcare Fund, L.P.追加投资的议案》,同意香港海普瑞决定对新元医疗基金追加

投资2,000万美元。详细内容参见2016年7月9日刊登于《证券时报》、《中国证券报》、《上海证券报》、

《证券日报》和巨潮资讯网 www.cninfo.com.cn 的《关于全资子公司对ORI Healthcare Fund, L.P.追加

投资的公告》。报告期内,香港海普瑞按照投资付款通知,支付投资款1,163,362.11美元。截止本公告日,

已累计支付25,741,815.88美元。

    5、 2016年6月16日,公司第三届董事会第二十二次会议审议通过《关于公司使用自有资金对TPG

BIOTECHNOLOGY PARTNERS V, L.P. 投 资 的 议 案 》 , 同 意 使 用 6,000 万 美 元 自 有 资 金 参 与 投 资 TPG

Biotechnology Partners V, L.P.。详细容参见2016年6月17日刊登于《证券时报》、《中国证券报》、

《上海证券报》、《证券日报》和巨潮资讯网 www.cninfo.com.cn 的《关于公司使用自有资金对TPG

BIOTECHNOLOGY PARTNERS V, L.P.投资的公告》。报告期内,公司按照投资付款通知,实际支付1,499,075

美元。截至本公告日,已累计支付27,380,576.00 美元。

    6、 2016年9月20日,第三届董事会第二十六次会议审议通过了《关于对全资子公司海普瑞(香港)

有限公司进行增资的议案》,同意公司以自有资金5,500万美元(或等值人民币)增加对香港海普瑞的投

资,详细内容参见2016年9月21日刊登于《证券时报》、《中国证券报》、《上海证券报》、《证券日报》

和巨潮资讯网 www.cninfo.com.cn 的《关于对全资子公司海普瑞(香港)有限公司进行增资的公告》。

截至本公告日,该项增资尚未完成。

    7、 2016年11月18日,第三届董事会第二十八会议审议通过了《关于对全资子公司Hepalink USA Inc.

增资的议案》,同意公司以自有资金折合人民币5亿元增加对美国海普瑞的投资,详细内容参见2016年11

月19日刊登于《证券时报》、《中国证券报》、《上海证券报》、《证券日报》和巨潮资讯网 www.cninfo.com.cn

的《关于对全资子公司Hepalink USA Inc.增资的公告》。截至本公告日,该项增资尚未完成。

    8、 2018年2月11日,公司第四届董事会第十一次会议审议通过了《关于审议公司购买资产暨关联交


                                                                                                        10
                                                    深圳市海普瑞药业集团股份有限公司 2018 年第三季度报告全文


易方案的议案》,经2018年第二次临时股东大会审议通过,本次收购多普乐方案改为现金方式收购,多普

乐已于2018年4月完成工商登记变更并取得新的营业执照,根据收购协议,多普乐于第三季度开始纳入公

司合并报表范围。详细内容参见2018年4月4日及2018年7月2日刊登于《证券时报》、《中国证券报》、《上

海证券报》、《证券日报》和巨潮资讯网 www.cninfo.com.cn 的《关于购买资产暨关联交易的进展公告》。

    9、 2018年2月11日,第四届董事会第十一次会议审议通过《关于公司与Aridis设立合资子公司的议

案》,同意公司认缴出资600万美元现金或等值货币,与Aridis在中国共同投资设立合资公司。详细内容

参见2018年2月12日刊登于《证券时报》、《中国证券报》、《上海证券报》、《证券日报》和巨潮资讯

网 www.cninfo.com.cn 的《关于公司与Aridis设立合资子公司的公告》。2018年8月,海普瑞与Aridis对

合资子公司瑞迪生物增资,详细内容参见2018年8月15日刊登于《证券时报》、《中国证券报》、《上海

证券报》、《证券日报》和巨潮资讯网 www.cninfo.com.cn 的《关于控股子公司取得产品授权暨对控股

子公司增资的公告》。

    10、 2018年6月6日,第四届董事会第十四次会议审议通过《关于控股子公司股权转让的议案》,同

意将公司持有成都市海通药业有限公司(以下简称“成都海通”)85%的股权转让给盘谷晨宸(上海)企

业管理中心(有限合伙)。详细内容参见2018年6月7日刊登于《证券时报》、《中国证券报》、《上海证

券报》、《证券日报》和巨潮资讯网 www.cninfo.com.cn 的《关于控股子公司股权转让的公告》。成都

海通已完成工商登记变更,将不再纳入公司合并报表范围。详细内容参见2018.07.14日刊登于《证券时报》、

《中国证券报》、《上海证券报》、《证券日报》和巨潮资讯网 www.cninfo.com.cn 的《关于控股子公

司股权转让的进展公告》。

           重要事项概述                  披露日期                        临时报告披露网站查询索引

                                                            http://www.szse.cn/disclosure/listed/bulletinDetail/index.
关于控股子公司股权转让的进展公告     2018 年 06 月 07 日
                                                            html?62db85c3-9e6c-4c83-a312-c6c988011650

                                                            http://www.szse.cn/disclosure/listed/bulletinDetail/index.
关于购买资产暨关联交易的进展公告     2018 年 07 月 02 日
                                                            html?883baa31-e171-4060-b7f6-6dc7e577f344

                                                            http://www.szse.cn/disclosure/listed/bulletinDetail/index.
关于控股子公司股权转让的进展公告     2018 年 07 月 14 日
                                                            html?85863785-d423-43e3-876e-525c5380f5bc

关于控股子公司取得产品授权暨对控股                          http://www.szse.cn/disclosure/listed/bulletinDetail/index.
                                     2018 年 08 月 15 日
子公司增资的公告                                            html?6199b130-95ae-4124-9f25-ee1a36c65ac7




                                                                                                                    11
                                                          深圳市海普瑞药业集团股份有限公司 2018 年第三季度报告全文




     三、公司实际控制人、股东、关联方、收购人以及公司等承诺相关方在报告期内超期未履行完毕的承诺事项
√ 适用 □ 不适用

      承诺事由                承诺方       承诺类型                承诺内容               承诺时间 承诺期限 履行情况

股改承诺             不适用

收购报告书或权益变
                     不适用
动报告书中所作承诺

资产重组时所作承诺 不适用

                                                         1、在本公司作为公司控股股东
                                                         期间/在本人作为公司实际控制
                                                         人期间/在本人作为公司董事、总
                     深圳市乐仁科技有限                  经理期间,本公司/本人保证不自
                     公司;乌鲁木齐飞来                  营或以合资、合作等方式经营任                       报告期
                                          关于同业竞
                     石股权投资有限公                    何与公司现从事的业务有竞争                         内,承诺
                                          争、关联交                                     2010 年 04
                     司;乌鲁木齐金田土                  的业务,本公司现有的或将来成                       人严格履
                                          易、资金占用                                   月 23 日
                     股权投资合伙企业                    立的全资子公司、控股子公司以                       行了上述
                                         方面的承诺
                     (有限合伙);李锂;                及其他受本公司控制的企业亦                         承诺
                     李坦;单宇                          不会经营与公司现从事的业务
                                                         有竞争的业务。2、如违反上述
                                                         承诺,本公司同意承担给公司造
                                                         成的全部损失。

                                                         1、如今后公司或子公司深圳市
                                                         多普生生物技术有限公司因依
                                                         据深府[1988]232 号文享受的
首次公开发行或再融
                                                         企业所得税优惠被税务机关撤
资时所作承诺
                                                         消而产生的额外税项和费用时,
                                                         将及时、无条件、全额返还公司
                                                                                                            报告期
                     深圳市乐仁科技有限                  或深圳市多普生生物技术有限
                                                                                                            内,承诺
                     公司;乌鲁木齐金田                  公司补缴的税款以及因此所产      2010 年 04
                                          其他承诺                                                          人严格履
                     土股权投资合伙企业                  生的所有相关费用。2、如今后 月 23 日
                                                                                                            行了上述
                     (有限合伙)                        公司因以实际缴纳的增值税和
                                                                                                            承诺
                                                         营业税税额为计税依据缴纳城
                                                         市维护建设税和教育费附加事
                                                         宜被税务机关追缴而产生额外
                                                         税项和费用时,将及时、无条件、
                                                         全额返还公司补缴的税款以及
                                                         因此所产生的所有相关费用。

                     深圳市乐仁科技有限                  如今后公司或子公司深圳市多                         报告期
                     公司;乌鲁木齐金田                  普生生物技术有限公司因上市      2010 年 04         内,承诺
                                          其他承诺
                     土股权投资合伙企业                  前执行住房公积金政策事宜被      月 23 日           人严格履
                     (有限合伙)                        要求补缴住房公积金、缴纳罚款                       行了上述


                                                                                                                     12
                                                              深圳市海普瑞药业集团股份有限公司 2018 年第三季度报告全文


                                                             或因此遭受任何损失时,将及                              承诺
                                                             时、无条件、全额返还公司或深
                                                             圳市多普生生物技术有限公司
                                                             由此遭受的一切损失。

股权激励承诺          不适用

其他对公司中小股东
                      不适用
所作承诺

承诺是否按时履行      是

如承诺超期未履行完
毕的,应当详细说明
未完成履行的具体原 不适用
因及下一步的工作计



四、对 2018 年度经营业绩的预计

2018 年度预计的经营业绩情况:归属于上市公司股东的净利润为正值且不属于扭亏为盈的情形
归属于上市公司股东的净利润为正值且不属于扭亏为盈的情形

2018 年度归属于上市公司股东的净利润变动幅
                                                                           349.25%        至                         398.74%


2018 年度归属于上市公司股东的净利润变动区
                                                                             59,000       至                             65,500
间(万元)

2017 年度归属于上市公司股东的净利润(万元)                                                                          13,133.03

                                                  1、海普瑞和 SPL 肝素原料药销售量上升和销售价格上涨带来毛利增加;2、
                                                  SPL 胰酶原料药销售增长;3、2018 年海普瑞收购多普乐纳入合并范围带
业绩变动的原因说明                                来净利润增加,但同时抵消了海普瑞肝素原料药关联交易所产生的利润;4、
                                                  按照权益法合并 Resverlogix 的投资导致投资损失增加;5、由于人民币贬
                                                  值带来和内部往来有关的汇兑收益增加。


五、以公允价值计量的金融资产

√ 适用 □ 不适用
                                                                                                                      单位:元

                                            计入权益的累
 资产                      本期公允价值                      报告期内购    报告期内售     累计投资收                      资金
        初始投资成本                        计公允价值变                                                  期末金额
 类别                        变动损益                          入金额        出金额            益                         来源
                                                 动

                                                                                                                         自有
股票       89,790,912.41 -168,779,934.32     66,579,018.94                 4,000,302.16    6,867,365.68 156,369,931.35
                                                                                                                         资金

                                                                                                                         自有
基金    330,875,056.56       5,166,742.47   -17,047,504.13 57,217,020.99   1,806,820.35    3,587,094.51 313,827,552.43
                                                                                                                         资金



                                                                                                                              13
                                                         深圳市海普瑞药业集团股份有限公司 2018 年第三季度报告全文


合计    420,665,968.97 -163,613,191.85   49,531,514.81 57,217,020.99   5,807,122.51 10,454,460.19 470,197,483.78    --


六、违规对外担保情况

□ 适用 √ 不适用
公司报告期无违规对外担保情况。


七、控股股东及其关联方对上市公司的非经营性占用资金情况

□ 适用 √ 不适用
公司报告期不存在控股股东及其关联方对上市公司的非经营性占用资金。


八、委托理财

√ 适用 □ 不适用
                                                                                                             单位:万元

       具体类型         委托理财的资金来源         委托理财发生额             未到期余额          逾期未收回的金额

券商理财产品           自有资金                                  15,000                  15,000                          0

银行理财产品           自有资金                                  17,550                  11,550                          0

合计                                                             32,550                  26,550                          0

单项金额重大或安全性较低、流动性较差、不保本的高风险委托理财具体情况
□ 适用 √ 不适用
委托理财出现预期无法收回本金或存在其他可能导致减值的情形
□ 适用 √ 不适用


九、报告期内接待调研、沟通、采访等活动登记表

√ 适用 □ 不适用

        接待时间                   接待方式                  接待对象类型                  调研的基本情况索引

                                                                                 http://www.cninfo.com.cn/finalpage/201
2018 年 07 月 23 日       实地调研                    机构
                                                                                 8-07-25/1205228288.PDF




                                                                                                                         14
                                              深圳市海普瑞药业集团股份有限公司 2018 年第三季度报告全文




                                        第四节 财务报表

一、财务报表

1、合并资产负债表

编制单位:深圳市海普瑞药业集团股份有限公司
                                                                                                单位:元

                  项目                       期末余额                           期初余额

流动资产:

    货币资金                                            2,372,117,010.84              3,597,128,234.63

    结算备付金

    拆出资金

    以公允价值计量且其变动计入当期
损益的金融资产

    衍生金融资产

    应收票据及应收账款                                   821,423,722.07                 727,039,623.75

      其中:应收票据                                         270,000.00                    11,096,447.98

               应收账款                                  821,153,722.07                 715,943,175.77

    预付款项                                             229,012,508.28                 271,740,927.66

    应收保费

    应收分保账款

    应收分保合同准备金

    其他应收款                                           235,653,956.87                 375,111,510.85

    买入返售金融资产

    存货                                                1,583,421,062.59              1,291,055,189.32

    持有待售资产

    一年内到期的非流动资产

    其他流动资产                                         464,613,992.80                 396,590,774.62

流动资产合计                                            5,706,242,253.45              6,658,666,260.83

非流动资产:

    发放贷款及垫款

    可供出售金融资产                                    1,724,887,272.39              1,461,532,170.16

    持有至到期投资



                                                                                                      15
                                     深圳市海普瑞药业集团股份有限公司 2018 年第三季度报告全文


    长期应收款                                  6,413,640.17                     2,529,274.60

    长期股权投资                             365,717,491.67                    621,440,389.73

    投资性房地产

    固定资产                                1,142,779,242.18                 1,105,782,828.63

    在建工程                                 909,121,516.70                    770,912,629.67

    生产性生物资产

    油气资产

    无形资产                                 693,035,530.64                    707,127,205.90

    开发支出                                  14,378,087.31                     12,644,460.61

    商誉                                    2,322,164,174.72                 2,205,704,900.35

    长期待摊费用                             214,820,498.40                    216,027,877.64

    递延所得税资产                           177,448,942.85                    159,759,290.80

    其他非流动资产                           264,251,748.83                    289,346,655.08

非流动资产合计                              7,835,018,145.86                 7,552,807,683.17

资产总计                                   13,541,260,399.31                14,211,473,944.00

流动负债:

    短期借款                                1,638,856,659.61                 1,689,802,442.00

    向中央银行借款

    吸收存款及同业存放

    拆入资金

    以公允价值计量且其变动计入当期
损益的金融负债

    衍生金融负债

    应付票据及应付账款                       287,468,211.60                    187,288,194.45

    预收款项                                 162,163,186.70                     70,181,022.14

    卖出回购金融资产款

    应付手续费及佣金

    应付职工薪酬                             104,599,939.66                     96,245,863.75

    应交税费                                 108,900,914.54                     31,040,540.12

    其他应付款                              1,398,006,155.20                   252,719,705.59

    应付分保账款

    保险合同准备金

    代理买卖证券款

    代理承销证券款




                                                                                           16
                                          深圳市海普瑞药业集团股份有限公司 2018 年第三季度报告全文


    持有待售负债

    一年内到期的非流动负债                       1,027,025,577.04                 1,577,762,267.59

    其他流动负债                                     1,907,119.10                     2,933,348.74

流动负债合计                                     4,728,927,763.45                 3,907,973,384.38

非流动负债:

    长期借款                                     1,472,642,746.08                   831,819,445.60

    应付债券                                      994,147,014.79                    992,786,797.79

      其中:优先股

               永续债

    长期应付款                                     84,132,634.03                     77,850,913.48

    长期应付职工薪酬

    预计负债                                         9,463,300.07                     8,988,704.41

    递延收益                                       29,574,859.60                     42,344,909.20

    递延所得税负债                                302,654,246.64                    316,170,052.97

    其他非流动负债

非流动负债合计                                   2,892,614,801.21                 2,269,960,823.45

负债合计                                         7,621,542,564.66                 6,177,934,207.83

所有者权益:

    股本                                         1,247,201,704.00                 1,247,201,704.00

    其他权益工具

      其中:优先股

               永续债

    资本公积                                     2,147,908,689.56                 4,550,075,084.56

    减:库存股

    其他综合收益                                  145,528,444.81                    229,456,893.23

    专项储备

    盈余公积                                      490,284,765.67                    490,284,765.67

    一般风险准备

    未分配利润                                   1,805,150,045.47                 1,410,321,047.80

归属于母公司所有者权益合计                       5,836,073,649.51                 7,927,339,495.26

    少数股东权益                                   83,644,185.14                    106,200,240.91

所有者权益合计                                   5,919,717,834.65                 8,033,539,736.17

负债和所有者权益总计                            13,541,260,399.31                14,211,473,944.00


法定代表人:李锂             主管会计工作负责人:张斌                       会计机构负责人:张斌


                                                                                                17
                                        深圳市海普瑞药业集团股份有限公司 2018 年第三季度报告全文


2、母公司资产负债表

                                                                                          单位:元

                   项目                期末余额                           期初余额

流动资产:

    货币资金                                      2,019,005,493.23              3,227,938,630.55

    以公允价值计量且其变动计入当期损
益的金融资产

    衍生金融资产

    应收票据及应收账款                            1,082,238,219.23                626,782,984.03

      其中:应收票据                               120,270,000.00                 133,563,701.92

               应收账款                            961,968,219.23                 493,219,282.11

    预付款项                                       417,000,386.24                 483,539,793.06

    其他应收款                                    1,043,567,287.22                779,647,556.13

    存货                                           309,543,091.69                 429,866,372.13

    持有待售资产

    一年内到期的非流动资产

    其他流动资产                                   256,018,014.08                 272,058,420.27

流动资产合计                                      5,127,372,491.69              5,819,833,756.17

非流动资产:

    可供出售金融资产                               542,774,790.96                 608,207,193.47

    持有至到期投资

    长期应收款                                     963,775,920.00                 808,825,820.00

    长期股权投资                                  2,522,925,648.83              2,375,604,730.39

    投资性房地产

    固定资产                                       162,505,909.11                 177,172,471.88

    在建工程                                       578,521,346.25                 435,048,205.40

    生产性生物资产

    油气资产

    无形资产                                        99,856,385.88                 103,591,834.85

    开发支出                                           103,819.45                       76,098.55

    商誉

    长期待摊费用                                    95,616,225.63                    91,904,723.27

    递延所得税资产                                  47,688,582.77                    10,339,956.39

    其他非流动资产                                  78,122,257.22                    37,796,177.17



                                                                                                18
                                       深圳市海普瑞药业集团股份有限公司 2018 年第三季度报告全文


非流动资产合计                                5,091,890,886.10                 4,648,567,211.37

资产总计                                     10,219,263,377.79                10,468,400,967.54

流动负债:

    短期借款                                  1,224,311,804.61                 1,361,047,500.00

    以公允价值计量且其变动计入当期损
益的金融负债

    衍生金融负债

    应付票据及应付账款                          21,529,997.55                     30,431,059.43

    预收款项                                    12,804,053.95

    应付职工薪酬                                44,208,842.27                     39,860,373.80

    应交税费                                    56,513,862.49                     11,720,048.91

    其他应付款                                1,485,875,332.50                   152,896,958.75

    持有待售负债

    一年内到期的非流动负债

    其他流动负债

流动负债合计                                  2,845,243,893.37                 1,595,955,940.89

非流动负债:

    长期借款                                   545,280,000.00

    应付债券                                   994,147,014.79                    992,786,797.79

      其中:优先股

               永续债

    长期应付款

    长期应付职工薪酬

    预计负债

    递延收益                                      5,236,614.19                    10,253,643.13

    递延所得税负债                                4,727,729.03                    30,524,140.29

    其他非流动负债

非流动负债合计                                1,549,391,358.01                 1,033,564,581.21

负债合计                                      4,394,635,251.38                 2,629,520,522.10

所有者权益:

    股本                                      1,247,201,704.00                 1,247,201,704.00

    其他权益工具

      其中:优先股

               永续债




                                                                                             19
                                        深圳市海普瑞药业集团股份有限公司 2018 年第三季度报告全文


    资本公积                                      2,261,958,224.01              4,248,203,399.82

    减:库存股

    其他综合收益                                     70,727,198.49                  216,906,862.41

    专项储备

    盈余公积                                        490,284,765.67                  490,284,765.67

    未分配利润                                    1,754,456,234.24              1,636,283,713.54

所有者权益合计                                    5,824,628,126.41              7,838,880,445.44

负债和所有者权益总计                             10,219,263,377.79             10,468,400,967.54


3、合并本报告期利润表

                                                                                          单位:元

                 项目              本期发生额                          上期发生额

一、营业总收入                              1,123,690,714.25                        721,469,457.15

    其中:营业收入                          1,123,690,714.25                        721,469,457.15

          利息收入

          已赚保费

          手续费及佣金收入

二、营业总成本                                  812,653,994.33                      637,020,816.80

    其中:营业成本                              677,537,239.04                      483,381,822.12

          利息支出

          手续费及佣金支出

          退保金

          赔付支出净额

          提取保险合同准备金净额

          保单红利支出

          分保费用

          税金及附加                              8,780,514.78                       10,196,088.31

          销售费用                               54,510,216.18                       38,194,889.23

          管理费用                              110,348,758.10                       58,770,969.87

          研发费用                                6,445,554.94                       26,547,756.84

          财务费用                              -47,288,570.35                       15,268,926.84

            其中:利息费用                       48,077,291.86                       33,474,663.23

                    利息收入                     17,207,815.42                       49,152,262.28

          资产减值损失                            2,320,281.64                        4,660,363.59



                                                                                                20
                                         深圳市海普瑞药业集团股份有限公司 2018 年第三季度报告全文


       加:其他收益                             4,333,494.18                         2,825,702.60

           投资收益(损失以“-”号填
                                              -74,464,036.35                          -256,547.10
列)

             其中:对联营企业和合营
                                             -123,755,058.55                          -625,125.49
企业的投资收益

           公允价值变动收益(损失以
                                                3,289,101.93
“-”号填列)

           汇兑收益(损失以“-”号填
列)

           资产处置收益(损失以“-”号
                                                    1,944.30                          819,065.31
填列)

三、营业利润(亏损以“-”号填列)           244,197,223.98                         87,836,861.16

       加:营业外收入                           3,390,275.93                          998,941.08

       减:营业外支出                             22,590.60                          1,581,389.06

四、利润总额(亏损总额以“-”号填
                                             247,564,909.31                         87,254,413.18
列)

       减:所得税费用                         45,136,103.56                         10,667,543.82

五、净利润(净亏损以“-”号填列)           202,428,805.75                         76,586,869.36

       (一)持续经营净利润(净亏损
                                             202,428,805.75                         76,586,869.36
以“-”号填列)

       (二)终止经营净利润(净亏损
以“-”号填列)

       归属于母公司所有者的净利润            206,706,175.00                         78,602,888.85

       少数股东损益                            -4,277,369.25                        -2,016,019.49

六、其他综合收益的税后净额                    31,994,278.65                        -28,557,709.74

  归属母公司所有者的其他综合收益
                                              31,895,781.67                        -28,303,779.48
的税后净额

       (一)不能重分类进损益的其他
综合收益

             1.重新计量设定受益计划
变动额

             2.权益法下不能转损益的
其他综合收益

       (二)将重分类进损益的其他综
                                              31,895,781.67                        -28,303,779.48
合收益

             1.权益法下可转损益的其
他综合收益



                                                                                               21
                                                     深圳市海普瑞药业集团股份有限公司 2018 年第三季度报告全文


            2.可供出售金融资产公允
                                                             -7,869,380.87                        -10,341,457.01
价值变动损益

            3.持有至到期投资重分类
为可供出售金融资产损益

            4.现金流量套期损益的有
效部分

            5.外币财务报表折算差额                           39,765,162.54                        -17,962,322.47

            6.其他

  归属于少数股东的其他综合收益的
                                                                 98,496.98                           -253,930.26
税后净额

七、综合收益总额                                            234,423,084.40                         48,029,159.62

       归属于母公司所有者的综合收益
                                                            238,601,956.67                         50,299,109.37
总额

       归属于少数股东的综合收益总额                          -4,178,872.27                         -2,269,949.75

八、每股收益:

       (一)基本每股收益                                          0.1657                                0.0630

       (二)稀释每股收益                                          0.1657                                0.0630

本期发生同一控制下企业合并的,被合并方在合并前实现的净利润为:0 元,上期被合并方实现的净利润为:-11,890,946.56
元。


法定代表人:李锂                        主管会计工作负责人:张斌                        会计机构负责人:张斌


4、母公司本报告期利润表

                                                                                                        单位:元

                 项目                          本期发生额                            上期发生额

一、营业收入                                                603,320,053.72                        319,285,426.53

       减:营业成本                                         379,580,344.32                        295,047,763.05

           税金及附加                                          643,157.39                           2,906,523.44

           销售费用                                           3,182,277.03                           584,140.17

           管理费用                                          27,655,552.38                         26,516,817.34

           研发费用                                           8,792,294.00                         13,535,817.62

           财务费用                                         -45,259,581.62                        -23,102,803.51

            其中:利息费用                                   25,610,154.18                         13,426,420.91

                     利息收入                                19,859,980.35                         58,503,020.80

           资产减值损失                                          19,501.09                          1,254,007.30

       加:其他收益                                           1,182,342.98                           198,342.98



                                                                                                              22
                                         深圳市海普瑞药业集团股份有限公司 2018 年第三季度报告全文


           投资收益(损失以“-”号填
                                             -107,987,208.49                          107,521.32
列)

           其中:对联营企业和合营企
                                             -117,948,605.60
业的投资收益

           公允价值变动收益(损失以
                                                3,289,101.93
“-”号填列)

           资产处置收益(损失以“-”号
                                                                                      393,309.40
填列)

二、营业利润(亏损以“-”号填列)           125,190,745.55                          3,242,334.82

       加:营业外收入                                   0.17

       减:营业外支出                             11,863.77                           901,965.98

三、利润总额(亏损总额以“-”号填
                                             125,178,881.95                          2,340,368.84
列)

       减:所得税费用                         18,211,152.29                          1,396,731.33

四、净利润(净亏损以“-”号填列)           106,967,729.66                           943,637.51

       (一)持续经营净利润(净亏损
                                             106,967,729.66                           943,637.51
以“-”号填列)

       (二)终止经营净利润(净亏损
以“-”号填列)

五、其他综合收益的税后净额                     -5,025,456.18                        -3,940,421.24

       (一)不能重分类进损益的其他
综合收益

             1.重新计量设定受益计划
变动额

             2.权益法下不能转损益的
其他综合收益

       (二)将重分类进损益的其他综
                                               -5,025,456.18                        -3,940,421.24
合收益

             1.权益法下可转损益的其
他综合收益

             2.可供出售金融资产公允
                                               -5,025,456.18                        -3,940,421.24
价值变动损益

             3.持有至到期投资重分类
为可供出售金融资产损益

             4.现金流量套期损益的有
效部分

             5.外币财务报表折算差额

             6.其他


                                                                                               23
                                             深圳市海普瑞药业集团股份有限公司 2018 年第三季度报告全文


六、综合收益总额                                     101,942,273.48                       -2,996,783.73

七、每股收益:

       (一)基本每股收益

       (二)稀释每股收益


5、合并年初到报告期末利润表

                                                                                               单位:元

                 项目                   本期发生额                          上期发生额

一、营业总收入                                   3,332,009,386.88                    1,868,188,195.43

       其中:营业收入                            3,332,009,386.88                    1,868,188,195.43

             利息收入

             已赚保费

             手续费及佣金收入

二、营业总成本                                   2,635,147,334.67                    1,791,637,351.08

       其中:营业成本                            2,019,706,086.22                    1,313,069,041.93

             利息支出

             手续费及佣金支出

             退保金

             赔付支出净额

             提取保险合同准备金净额

             保单红利支出

             分保费用

             税金及附加                               15,825,554.36                       17,595,519.06

             销售费用                                189,076,617.66                       73,192,717.56

             管理费用                                272,931,613.21                      248,824,555.71

             研发费用                                116,546,165.76                       67,521,505.52

             财务费用                                 15,037,943.91                       66,030,264.56

               其中:利息费用                        138,796,495.79                      105,226,712.13

                      利息收入                        50,586,192.50                      106,684,259.97

             资产减值损失                              6,023,353.55                        5,403,746.74

       加:其他收益                                   21,330,727.05                       14,161,619.72

           投资收益(损失以“-”号填
                                                 -187,693,804.55                           1,436,834.40
列)

           其中:对联营企业和合营企              -258,174,079.31                          -5,876,408.51



                                                                                                     24
                                         深圳市海普瑞药业集团股份有限公司 2018 年第三季度报告全文


业的投资收益

           公允价值变动收益(损失以
                                                                                    -6,987,616.08
“-”号填列)

           汇兑收益(损失以“-”号填
列)

           资产处置收益(损失以“-”号
                                                 118,064.09                           867,055.21
填列)

三、营业利润(亏损以“-”号填列)           530,617,038.80                         86,028,737.60

       加:营业外收入                           7,133,506.61                         1,123,145.70

       减:营业外支出                            167,785.36                          2,049,480.91

四、利润总额(亏损总额以“-”号填
                                             537,582,760.05                         85,102,402.39
列)

       减:所得税费用                        108,635,809.02                         10,465,069.56

五、净利润(净亏损以“-”号填列)           428,946,951.03                         74,637,332.83

       (一)持续经营净利润(净亏损
                                             428,946,951.03                         74,637,332.83
以“-”号填列)

       (二)终止经营净利润(净亏损
以“-”号填列)

       归属于母公司所有者的净利润            450,883,299.07                         82,889,507.66

       少数股东损益                           -21,936,348.04                        -8,252,174.83

六、其他综合收益的税后净额                    -84,130,321.69                      -165,860,440.59

  归属母公司所有者的其他综合收益
                                              -83,928,448.43                      -166,683,034.48
的税后净额

       (一)不能重分类进损益的其他
综合收益

             1.重新计量设定受益计划
变动额

             2.权益法下不能转损益的
其他综合收益

       (二)将重分类进损益的其他综
                                              -83,928,448.43                      -166,683,034.48
合收益

             1.权益法下可转损益的其
他综合收益

             2.可供出售金融资产公允
                                             -132,496,578.99                      -134,382,088.47
价值变动损益

             3.持有至到期投资重分类
为可供出售金融资产损益




                                                                                               25
                                                    深圳市海普瑞药业集团股份有限公司 2018 年第三季度报告全文


             4.现金流量套期损益的有
效部分

             5.外币财务报表折算差额                         48,568,130.56                        -32,300,946.01

             6.其他

  归属于少数股东的其他综合收益的
                                                              -201,873.26                           822,593.89
税后净额

七、综合收益总额                                           344,816,629.34                        -91,223,107.76

       归属于母公司所有者的综合收益
                                                           366,954,850.64                        -83,793,526.82
总额

       归属于少数股东的综合收益总额                        -22,138,221.30                         -7,429,580.94

八、每股收益:

       (一)基本每股收益                                         0.3615                                0.0665

       (二)稀释每股收益                                         0.3615                                0.0665

本期发生同一控制下企业合并的,被合并方在合并前实现的净利润为:61,177,988.97,上期被合并方实现的净利润为:
5,775,207.89 元。


6、母公司年初到报告期末利润表

                                                                                                       单位:元

                 项目                         本期发生额                            上期发生额

一、营业收入                                            1,614,734,348.55                         733,305,237.28

       减:营业成本                                     1,114,434,181.30                         583,328,338.51

           税金及附加                                        2,527,291.54                          7,804,888.56

           销售费用                                          7,753,579.34                          2,596,060.04

           管理费用                                         67,904,660.13                         82,140,068.85

           研发费用                                         34,612,514.62                         31,937,235.79

           财务费用                                        -43,115,142.79                        -41,257,029.03

             其中:利息费用                                 72,616,134.09                         38,471,508.68

                      利息收入                              57,818,899.79                        136,214,559.31

           资产减值损失                                      3,593,432.34                          1,237,564.50

       加:其他收益                                          4,497,228.94                          1,131,623.89

           投资收益(损失以“-”号填
                                                        -229,036,964.25                            9,015,350.19
列)

           其中:对联营企业和合营企
                                                        -247,283,905.75
业的投资收益

           公允价值变动收益(损失以
                                                                                                  -6,987,616.08
“-”号填列)


                                                                                                             26
                                         深圳市海普瑞药业集团股份有限公司 2018 年第三季度报告全文


           资产处置收益(损失以“-”号
                                                                                      393,309.40
填列)

二、营业利润(亏损以“-”号填列)           202,484,096.76                         69,070,777.46

       加:营业外收入                               3,980.17                           20,000.00

       减:营业外支出                             12,236.50                           906,008.13

三、利润总额(亏损总额以“-”号填
                                             202,475,840.43                         68,184,769.33
列)

       减:所得税费用                         28,179,243.05                         10,227,715.41

四、净利润(净亏损以“-”号填列)           174,296,597.38                         57,957,053.92

       (一)持续经营净利润(净亏损
                                             174,296,597.38                         57,957,053.92
以“-”号填列)

       (二)终止经营净利润(净亏损
以“-”号填列)

五、其他综合收益的税后净额                   -139,832,545.43                      -119,204,020.54

       (一)不能重分类进损益的其他
综合收益

             1.重新计量设定受益计划
变动额

             2.权益法下不能转损益的
其他综合收益

       (二)将重分类进损益的其他综
                                             -139,832,545.43                      -119,204,020.54
合收益

             1.权益法下可转损益的其
他综合收益

             2.可供出售金融资产公允
                                             -139,832,545.43                      -119,204,020.54
价值变动损益

             3.持有至到期投资重分类
为可供出售金融资产损益

             4.现金流量套期损益的有
效部分

             5.外币财务报表折算差额

             6.其他

六、综合收益总额                              34,464,051.95                        -61,246,966.62

七、每股收益:

       (一)基本每股收益

       (二)稀释每股收益




                                                                                               27
                                         深圳市海普瑞药业集团股份有限公司 2018 年第三季度报告全文


7、合并年初到报告期末现金流量表

                                                                                           单位:元

               项目                 本期发生额                          上期发生额

一、经营活动产生的现金流量:

     销售商品、提供劳务收到的现金            3,299,579,873.22                    1,849,406,495.34

     客户存款和同业存放款项净增加


     向中央银行借款净增加额

     向其他金融机构拆入资金净增加


     收到原保险合同保费取得的现金

     收到再保险业务现金净额

     保户储金及投资款净增加额

     处置以公允价值计量且其变动计
入当期损益的金融资产净增加额

     收取利息、手续费及佣金的现金

     拆入资金净增加额

     回购业务资金净增加额

     收到的税费返还                              112,531,773.75                       21,921,262.85

     收到其他与经营活动有关的现金                261,034,151.73                      182,462,027.23

经营活动现金流入小计                         3,673,145,798.70                    2,053,789,785.42

     购买商品、接受劳务支付的现金            2,128,216,898.11                    1,807,811,390.66

     客户贷款及垫款净增加额

     存放中央银行和同业款项净增加


     支付原保险合同赔付款项的现金

     支付利息、手续费及佣金的现金

     支付保单红利的现金

     支付给职工以及为职工支付的现
                                                 489,592,357.72                      425,890,263.85


     支付的各项税费                              100,889,102.88                       75,735,055.88

     支付其他与经营活动有关的现金                460,191,691.98                      208,559,668.53

经营活动现金流出小计                         3,178,890,050.69                    2,517,996,378.92

经营活动产生的现金流量净额                       494,255,748.01                   -464,206,593.50

二、投资活动产生的现金流量:


                                                                                                 28
                                      深圳市海普瑞药业集团股份有限公司 2018 年第三季度报告全文


       收回投资收到的现金                 499,154,687.30                      1,457,745,000.00

       取得投资收益收到的现金              17,365,721.39                         21,614,002.55

       处置固定资产、无形资产和其他
                                              315,513.85                          1,018,401.00
长期资产收回的现金净额

       处置子公司及其他营业单位收到
                                           27,172,101.72
的现金净额

       收到其他与投资活动有关的现金            27,906.19                         24,519,332.47

投资活动现金流入小计                      544,035,930.45                      1,504,896,736.02

       购建固定资产、无形资产和其他
                                          336,368,133.17                        523,057,670.89
长期资产支付的现金

       投资支付的现金                     563,337,949.91                      1,489,695,619.92

       质押贷款净增加额

       取得子公司及其他营业单位支付
                                         1,223,999,900.00
的现金净额

       支付其他与投资活动有关的现金                                              13,177,699.80

投资活动现金流出小计                     2,123,705,983.08                     2,025,930,990.61

投资活动产生的现金流量净额              -1,579,670,052.63                      -521,034,254.59

三、筹资活动产生的现金流量:

       吸收投资收到的现金                     100,000.00

       其中:子公司吸收少数股东投资
                                              100,000.00
收到的现金

       取得借款收到的现金                2,799,333,114.11                     2,282,386,826.26

       发行债券收到的现金

       收到其他与筹资活动有关的现金          3,482,649.12                                 0.00

筹资活动现金流入小计                     2,802,915,763.23                     2,282,386,826.26

       偿还债务支付的现金                2,838,711,754.08                     1,347,440,052.28

       分配股利、利润或偿付利息支付
                                          115,127,677.61                        383,830,782.89
的现金

       其中:子公司支付给少数股东的
股利、利润

       支付其他与筹资活动有关的现金        25,100,477.15                         34,030,905.40

筹资活动现金流出小计                     2,978,939,908.84                     1,765,301,740.57

筹资活动产生的现金流量净额                -176,024,145.61                       517,085,085.69

四、汇率变动对现金及现金等价物的
                                           42,272,277.90                        -13,379,674.44
影响

五、现金及现金等价物净增加额            -1,219,166,172.33                      -481,535,436.84



                                                                                            29
                                         深圳市海普瑞药业集团股份有限公司 2018 年第三季度报告全文


     加:期初现金及现金等价物余额            3,591,283,183.17                    4,665,417,416.46

六、期末现金及现金等价物余额                 2,372,117,010.84                    4,183,881,979.62


8、母公司年初到报告期末现金流量表

                                                                                           单位:元

               项目                 本期发生额                          上期发生额

一、经营活动产生的现金流量:

     销售商品、提供劳务收到的现金                858,643,799.76                      514,306,026.69

     收到的税费返还                               73,644,432.30                        8,943,876.08

     收到其他与经营活动有关的现金                375,874,890.85                       72,069,361.12

经营活动现金流入小计                         1,308,163,122.91                        595,319,263.89

     购买商品、接受劳务支付的现金                904,112,036.99                  1,021,169,845.74

     支付给职工以及为职工支付的现
                                                 127,256,726.25                      113,032,985.83


     支付的各项税费                               26,291,489.96                       43,018,572.05

     支付其他与经营活动有关的现金                244,694,511.84                       61,612,787.90

经营活动现金流出小计                         1,302,354,765.04                    1,238,834,191.52

经营活动产生的现金流量净额                         5,808,357.87                   -643,514,927.63

二、投资活动产生的现金流量:

     收回投资收到的现金                          421,528,825.81                  1,069,235,620.00

     取得投资收益收到的现金                        9,982,920.31                       20,795,778.88

     处置固定资产、无形资产和其他
                                                        500.00                          503,250.00
长期资产收回的现金净额

     处置子公司及其他营业单位收到
                                                  34,000,000.00
的现金净额

     收到其他与投资活动有关的现金

投资活动现金流入小计                             465,512,246.12                  1,090,534,648.88

     购建固定资产、无形资产和其他
                                                 188,297,396.21                      198,520,306.24
长期资产支付的现金

     投资支付的现金                              600,408,064.71                      959,153,138.62

     取得子公司及其他营业单位支付
                                             1,223,999,900.00
的现金净额

     支付其他与投资活动有关的现金                                                     13,144,771.00

投资活动现金流出小计                         2,012,705,360.92                    1,170,818,215.86

投资活动产生的现金流量净额                  -1,547,193,114.80                        -80,283,566.98



                                                                                                 30
                                      深圳市海普瑞药业集团股份有限公司 2018 年第三季度报告全文


三、筹资活动产生的现金流量:

       吸收投资收到的现金

       取得借款收到的现金                1,518,520,456.77                      1,304,676,109.59

       发行债券收到的现金

       收到其他与筹资活动有关的现金

筹资活动现金流入小计                     1,518,520,456.77                      1,304,676,109.59

       偿还债务支付的现金                1,129,195,000.00                       570,448,941.18

       分配股利、利润或偿付利息支付
                                           54,487,223.38                        320,557,735.77
的现金

       支付其他与筹资活动有关的现金        18,649,726.17                         26,631,912.29

筹资活动现金流出小计                     1,202,331,949.55                       917,638,589.24

筹资活动产生的现金流量净额                316,188,507.22                        387,037,520.35

四、汇率变动对现金及现金等价物的
                                           16,263,112.39                          -5,558,651.16
影响

五、现金及现金等价物净增加额            -1,208,933,137.32                      -342,319,625.42

       加:期初现金及现金等价物余额      3,227,938,630.55                      4,114,026,165.90

六、期末现金及现金等价物余额             2,019,005,493.23                      3,771,706,540.48


二、审计报告

第三季度报告是否经过审计
□ 是 √ 否
公司第三季度报告未经审计。




                                                            深圳市海普瑞药业集团股份有限公司


                                                                    法定代表人:李锂


                                                                     2018年10月29日




                                                                                             31
数据加载中...
prevnext
手机查看股票